References
- van Riel PL, Smolen JS, Emery P, Kalden JR, Dougados M, Strand CV, et al. Leflunomide: a manageable safety profile. J Rheumatol Suppl. 2004;71:21–4.
- Ochi S, Harigai M, Mizoguchi F, Iwai H, Hagiyama H, Oka T, et al. Leflunomide-related acute interstitial pneumonia in two patients with rheumatoid arthritis: autopsy findings with a mosaic pattern of acute and organizing diffuse alveolar damage. Mod Rheumatol. 2006;16:316–20.
- Saito E, Koike T, Hashimoto H, Miyasaka N, Ikeda Y, Hara M, et al. Efficacy of high-dose intravenous immunoglobulin therapy in Japanese patients with steroid-resistant polymyositis and der-matomyositis. Mod Rheumatol. 2008;18:34–44.
- Magyar E, Talerman A, Mohácsy J, Wouters HW, de Bruijn WC. Muscle changes in rheumatoid arthritis: a review of the literature with a study of 100 cases. Virchows Arch A Pathol Anat Histol. 1977;373: 267–78.
- Mini 6, Pedrol E, Casademont J, Garcia-Canasco M, Sanmarti R, Cebrik M, et al. Muscle involvement in rheumatoid arthritis: clinicopathological study of 21 symptomatic cases. Semin Arthritis Rheum. 1996;25: 421–8.
- Pitkeathly DA, Coomes EN. Polymyositis in rheumatoid arthritis. Ann Rheum Dis. 1966;25:127–32.
- Hall JT, Koopman WJ, Fallahi S, Oh SJ, Gay RE, Schrobenlober RE. Rheumatoid myositis clinical and histologic features and possible pathogenesis. Arthritis Rheum. 1984;27:737–43.
- Vela-Casasempere P, Borras-Blasco J, Navarro-Ruiz A. Alfuzosin-associated dermatomyositis. Br J Rheumatol. 1998;37:1135–6.
- Zilko PJ, Dawkins RL, Cohen ML. Penicillamine treatment of rheumatoid arthritis: relationship of proteinuria and autoanti-bodies to immune status. Proc R Soc Med. 1977;70[Suppl 31:118–22.
- Gomez Rodriguez N, Zulaica Garate A. Development of der-matomyositis in a woman with rheumatoid arthritis treated with leflunomide. An Med Int. 2005;22:300–1.
- Tam LS, Li EK, Wong CK, Lam CW, Li WC, Szeto CC. Safety and efficacy of leflunomide in the treatment of lupus nephritis refractory or intolerant to traditional immunosuppressive therapy: an open label trial. Ann Rheum Dis. 2006;65:417–8.
- Metzler C, Fink C, Lamprecht P, Gross WL, Reinhold-Keller E. Maintenance of remission with leflunomide in Wegener's gran-ulomatosis. Rheumatol (Oxf). 2004;43:315–20.
- Gensburger D, Kawashima M, Marotte H, Kanitakis J, Miossec P. Lupus erythematosus with leflunomide: induction or reactivation? Ann Rheum Dis. 2005;64:153–5.
- Chan AT, Bradlow A, McNally J. Leflunomide induced vascufitis-a dose-response relationship. Rheumatol (Oxf). 2003;42:492–3.
- Lange U, Piegsa M, Miiller-Ladner U, Strunk J. Anti-Jo-1 anti-body positive polymyositis-successful therapy with leflunomide. Autoimmunity. 2006;39: 261–4.
- Sangle VS, Sangle SR, D'Cruz DP. Leflunomide as a remission-maintaining therapy in difficult-to-treat dermatomyositis. Ann Rheum Dis. 2008;67:723.
- Cao WW, Kao PN, Aoki Y, Xu JC, Shorthouse RA, Morris RE. A novel mechanism of action of the immunomodulatory drug, leflunomide: augmentation of the immunosuppressive cytokine, TGF-beta 1, and suppression of the immunostimulatory cytokine, IL-2. Transplant Proc. 1996;28:3079–80.
- Lundberg I, Brengman JM, Engel AG. Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne dys-trophy, and non-weak controls. J Neuroimmunol. 1995;63:9–16.